A drug-drug interaction is a change in the effect or tolerability of a medicinal product caused by the concomitant administration of another active substance. Interactions can increase or decrease exposure, intensify adverse events, or reduce efficacy, and are therefore a central component of clinical development, pharmacovigilance, and benefit-risk assessment.
Mechanisms: pharmacokinetic and pharmacodynamic
Interactions are frequently classified into pharmacokinetic and pharmacodynamic mechanisms. Pharmacokinetic interactions affect absorption, distribution, metabolism, or elimination (ADME), thereby altering parameters such as AUC, Cmax, or half-life. Typical examples include enzyme induction or inhibition (e.g., CYP isoenzymes) and transporter interactions (e.g., P-gp, OATP). Pharmacodynamic interactions, in contrast, occur at the level of target effect, for instance through additive sedative effects or increased bleeding risk when combining antithrombotic therapies.
- Enzyme inhibition: If substrate concentration increases, dose-dependent toxicities may occur.
- Enzyme induction: If concentration decreases, loss of efficacy or therapeutic failure may result.
- Transporters: Changes in tissue distribution or renal elimination.
- Pharmacodynamics: Additive, synergistic, or antagonistic effects.
In development programs, these mechanisms are assessed early, typically within the framework of pharmacokinetics and pharmacodynamics, as well as through in vitro studies and model-based analyses. A common misconception is that interactions are only relevant with “strong” inhibitors. In practice, even moderate effects can be clinically significant if the therapeutic window is narrow or if vulnerable populations are included.
Study types and data sources for DDI assessment
The assessment of drug-drug interactions is based on various data sources: in vitro data (enzyme and transporter assays), clinical DDI studies in healthy volunteers or patient populations, population PK models, and simulations. Clinical DDI studies are frequently designed as crossover or sequential studies to reduce interindividual variability. For complex therapies—e.g., in oncology—real-world evidence and registry data are also used to detect rare interactions or interactions in polypharmacy.
Key elements in the clinical trial protocol include: selection of the “victim” and “perpetrator” drug, washout periods, standardization of dosing conditions, and predefined endpoints (e.g., geometric mean ratio of AUC/Cmax with confidence intervals). In addition, safety aspects must be considered, such as QT prolongation, bleeding risk, or hepatotoxic signals. Depending on the mechanism of action, special substudies may also be required, e.g., for biologics or for drugs with complex metabolism.
Relevance for authorization, labeling, and risk management
For marketing authorization, DDI assessment is central because it directly influences the product information: contraindications, dose adjustments, warnings, and monitoring recommendations. In Europe, DDI data are typically documented in modules of the electronic Common Technical Document and feed into the benefit-risk assessment. For clinically relevant interactions, measures are described in a Risk Management Plan, e.g., risk minimization measures, educational materials, or additional pharmacovigilance activities.
In the post-marketing phase, spontaneous reports, Periodic Safety Update Reports, and Post-Authorization Safety Studies can provide indications of previously unrecognized interactions. For Germany, requirements under the AMG and collaboration with authorities such as BfArM or PEI also play a role, particularly when safety measures must be communicated or label changes implemented.
Relevance for clinical trials
In clinical trials, drug-drug interactions influence several operational aspects: inclusion and exclusion criteria, permitted concomitant medication, protocol deviations, and safety monitoring. Especially in indications with polypharmacy, realistic concomitant medication management is crucial; otherwise, the study population and real-world care become too disconnected. In addition, investigators and study personnel must receive clear instructions on how to manage interaction risks, including dose adjustment, laboratory and ECG monitoring, and reporting pathways for adverse events.
From the perspective of sponsors and CROs, a robust DDI plan is important to avoid later delays: if interaction risks are recognized only late, amendments, additional studies, or restrictions in recruitment may become necessary. A structured DDI strategy therefore also supports lifecycle management and planning for further indications.
Frequently Asked Questions (FAQ)
When is an interaction considered clinically relevant?
This depends on the magnitude of exposure change, therapeutic window, and patient context. Even moderate changes can be relevant if, for example, toxicity thresholds are exceeded or loss of efficacy has serious consequences.
Why are DDI studies often conducted in healthy volunteers?
Healthy volunteers reduce confounding factors and allow clear interpretation of pharmacokinetics. However, in cases of safety risks or specific mechanisms, patient populations may be required.
How are DDI results implemented in the product information?
Typically through warnings, contraindications, dose recommendations, and monitoring. These measures are agreed with the authorities during the authorization procedure and can be further adapted after market launch.
Regulatory References
- EU Regulation (EU) No 536/2014 (CTR): Requirements for planning and documentation of clinical trials, including concomitant medication and safety monitoring.
- ICH E6(R3) Good Clinical Practice: Principles for protocol, documentation, and oversight in clinical trials.
- ICH E2A/E2B(R3) Pharmacovigilance: Framework for reporting and processing safety information, relevant for DDI signals after market launch.
In practice, it is also important to note that the technical infrastructure (device management, data transfer, backup, role and rights concept) should be tested before First-Patient-First-Visit. A Data Management Plan with clear responsibilities, monitoring strategy (e.g., remote monitoring), and defined quality metrics helps to detect deviations early and initiate CAPA measures. Training materials and documented instructions are also essential to achieve inspection readiness.
In practice, it is also important to note that the technical infrastructure (device management, data transfer, backup, role and rights concept) should be tested before First-Patient-First-Visit. A Data Management Plan with clear responsibilities, monitoring strategy (e.g., remote monitoring), and defined quality metrics helps to detect deviations early and initiate CAPA measures. Training materials and documented instructions are also essential to achieve inspection readiness.
In practice, it is also important to note that the technical infrastructure (device management, data transfer, backup, role and rights concept) should be tested before First-Patient-First-Visit. A Data Management Plan with clear responsibilities, monitoring strategy (e.g., remote monitoring), and defined quality metrics helps to detect deviations early and initiate CAPA measures. Training materials and documented instructions are also essential to achieve inspection readiness.